Association between serum cystatin C, monocytes and other inflammatory markers

Internal Medicine Journal

Volumn 42, Issue 5, 2012, Pages 517-522

  Evangelopoulos, A A ^a   Vallianou, N G ^a   Bountziouka, V ^b   Katsagoni, C ^b   Bathrellou, E ^b   Vogiatzakis, E D ^a   Bonou, M S ^a   Barbetseas, J ^a   Avgerinos, P C ^a   Panagiotakos, D B ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Atherosclerosis; Cystatin C; Monocyte; Renal function

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; FERRITIN; GLUCOSE; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; SERUM ALBUMIN; TRIACYLGLYCEROL;

ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LEUKOCYTE DIFFERENTIAL COUNT; LIFESTYLE; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CYSTATIN C; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MONOCYTES; RISK FACTORS;

EID: 84861433090     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02500.x     Document Type: Article

References (36)

1. Abrahamson M, Olafsson I, Palsdottir A, Ulsvback M, Lundwall A, Jensson O etal. Structure and expression of human cystatin C gene. Biochem J 1990; 268: 287-94.
2. Grubb AO. Cystatin C-properties and use as a diagnostic marker. Adv Clin Chem 2000; 35: 63-99.
3. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56: 409-14.
4. Bostom AG, Dworkin LD. Cystatin C measurement: improved detection of mild decrements in Glomerular Filtration Rate versus creatinine-based estimates? Am J Kidney Dis 2000; 36: 205-7.
5. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000; 37: 49-59.
6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
7. Fliser D, Ritz E. Serum cystatin C concentrations as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83.
8. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC etal. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-21.
9. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM etal. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75: 652-60.
10. Gaulteau MM, Guyon M, Guergen R, Siest G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001; 39: 850-7.
11. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM etal. Cystatin C and inflammatory markers in the ambulatory elderly. Am J Med 2005; 118: 1426e25-1416e31.
12. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944-7.
13. Wiegel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL etal. Cystatin C in downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS ONE 2009; 4: e7953.
14. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C etal. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Int Med 2006; 145: 237-46.
15. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Selinger SL, Newman AB etal. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-60.
16. Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 1990; 188: 16-22.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-9.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
19. Ichihara K, Saito K, Itoh Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med 2007; 45: 1232-6.
20. Getz GS. Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res 2005; 46: 1-10.
21. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-20.
22. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
23. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
24. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
25. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008; 18: 228-32.
26. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451: 904-13.
27. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JWA, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-7.
28. Chapman CM, Beilby JP, McQuillan BM, Stensland-Bugge E, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukine-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 2004; 35: 1619-24.
29. Huang ZS, Wang CH, Yip PK, Yang CY, Lee TK. In hypercholesterolemia, lower peripheral monocyte count is unique among the major predictors of atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 256-61.
30. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-83.
31. Oorni K, Sneck M, Bromme D, Pentikainen MO, Lindstedt KA, Mayranpaa M etal. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 2004; 279: 34776-84.
32. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP etal. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006; 113: 98-107.
33. Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH etal. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006; 26: 851-6.
34. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009; 55: 1932-43.
35. Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009. doi:10.1155/2009/137072
36. Neyat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant 2010; 25: 3283-9.